The study (NCT02486718) demonstrated an improvement in disease-free survival in patients with stage II to IIIA NSCLC who were treated with adjuvant atezolizumab after surgery, with more evident benefit in patients with PD-L1 expression (HR, 0.66; 95% CI, 0.50–0.88; p = 0.004) [66,67]. Here, CD274 is linked to non-small cell lung carcinoma.